

LIPIDS IN THE COMMUNITY

DATES:	Wednesday 16 – Friday 18 September 2014	Accreditation: CPD: Approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 15 category 1 (external) CPD credits. BDA endorsed
LOCATION:	de Havilland campus University of Hertfordshire, Hatfield AL10 9EU	
LOCAL HOST:	Dr Devi Nair, London, UK	

SESSION KEY:

Medical & Scientific programme	Healthcare & Patients programme	Study days	Sponsored symposia	Committee meetings	Social
--------------------------------	---------------------------------	------------	--------------------	--------------------	--------

PROGRAMME SUMMARY					
	MORNING	MID MORNING	MIDDAY	AFTERNOON	EVENING
WED	Allied Health Professional & Primary Care Study Day		HEART UK Committee Meetings - Hyperlipidaemia Education Study Day		Sponsored Symposia 1 Sponsored Symposia 2 - Welcome Buffet Reception - Guest speaker
THURS	Medical and Scientific Programme - Healthcare and Patients Programme			Clinical Lipidology Live! - redlacs Walk - Myant Lecture - HEART UK Annual General Meeting	Bollywood style Conference Dinner and dance
FRI	Poster session - Medical and Scientific Programme and Abstract Session - Healthcare and Patients Programme and Abstract Session			Presentation of Abstract Prizes - Closing Debate	

WEDNESDAY 16 SEPTEMBER

09:00 – 09:30 **Study day registration**
Weston Auditorium Foyer, Atrium

Allied Health Professional And Primary Care Study Day:

N101 – 1st floor, Atrium

THEME:

‘Practicalities in lipid management in Primary Care and beyond...’

Invitation to: *Primary Care • GP’s • GP registrars • Specialist Cardiovascular and Lipid Clinic Nurses • Practice Nurses • Genetics Specialist Nurses • Dietitians • Nutritionists • Allied Health Professionals*

Co-Chairs: *Linda Main and Nigel Scott*

09:30 – 09:55

SPEAKER 1:

LIPID GUIDELINES – LATEST UPDATE

The evolution of clinical guidelines for CVD prevention

Dr Alan Rees

Medical Director HEART UK & Vice President for Wales of the RCP, Cardiff, Wales, UK

09:55 – 10:05 Q&A

10:05 – 10:30

SPEAKER 2:

POINT OF CARE OR LABORATORY CHOLESTEROL TESTING

Dr Devi Nair

Consultant Chemical Pathologist and Head Of Department, Clinical Lead For Lipids and Cardiovascular Prevention, Director SAS Centre For Cardiac Bio-markers.
Royal Free Hospital, London, UK

10:30 – 10:40 Q&A

10:40 – 11:05

SPEAKER 3:

IMPLEMENTING NHS HEALTH CHECKS

Ms Michaela Nuttall

CVD Co-ordinator, Public Health Bromley

Ms Frances Fuller

CVD Prevention Programme Manager

Public Health Lewisham

11:05 – 11:15 Q&A

11:15 – 11:45

Refreshment break

Atrium

11:45 - 12:10

SPEAKER 4:

DEALING WITH HIGH RISK PATIENTS

A case- based discussion on how to deal with dyslipidaemia in patients at high risk of cardiovascular disease.

Dr Dev Datta

Consultant in Metabolic Medicine

Department of Biochemistry, Cardiff and Vale University Health Board, University Hospital Llandough, Llandough, Wales, UK

12:10 – 12:20 Q&A

12:20 – 12:45

SPEAKER 5:

MANAGING THE ISSUE OF STATIN INTOLERANCE – A PRIMARY CARE PERSPECTIVE

Statin intolerance polysymptomatology – can we treat it?

Dr Arun Gupta

GP

South Lewisham Group Practice, London, UK

12:45 – 12:55 Q&A

12:55 – 13:00

Concluding remarks and close

12:15 – 13:30

STUDY DAY LUNCH AND NETWORKING

Atrium

Hyperlipidaemia Education Study Day:

N105 – 1st floor, Atrium

THEME:

“Current Hyperlipidaemia Updates”

Invitation to: Scientists, PhD students, Consultants, SpR’s working within Clinical Chemistry, Endocrine and Diabetes, nurses and other involved in the field of lipidology and cardiovascular risk..

Co-Chairs: *Handrean Soran and Mary Seed*

13:15 – 13:40

SPEAKER 1:

UK, EUROPEAN AND INTERNATIONAL GUIDELINES – CONTRAST AND COMPARE

Dr Alan Rees

Medical Director HEART UK & Vice President for Wales of the RCP, Cardiff, Wales, UK

13:40 – 13:50 Q&A

13:50 – 14:15

SPEAKER 2:

TBC

14:15 – 14:25 Q&A

14:25 – 14:50

SPEAKER 3:

CHYLOMICRONAEMIA: CLINICAL AND LABORATORY PROBLEMS AND SOLUTIONS

Hypertriglyceridaemic pancreatitis due to chylomicronaemia presents specific problems of clinical management and laboratory investigation

Dr Michael France

Consultant Chemical Pathologist

Department of Clinical Biochemistry, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

14:50 – 15:00 Q&A

15:00 – 15:30

Refreshment break

Atrium

15:30 - 15:55

SPEAKER 4:

LP(a) UPDATED

Is it time for a reassessment with therapy on the distant horizon?

Dr Mary Seed

Consultant Physician, Lipid Clinic,

Charing Cross Hospital, London, UK

15:55 – 16:05 Q&A

16:05 – 16:30

SPEAKER 5:

MAKING FAMILIAL HYPERCHOLESTROLAEMIA FAMILIAR

Dr Devi Nair

Consultant Chemical Pathologist and Head Of Department, Clinical Lead For Lipids and Cardiovascular Prevention, Director SAS Centre For Cardiac Bio-markers.

Royal Free Hospital, London, UK

16:30 – 16:40 Q&A

16:40 - 17:00

Open discussion


17:00 Workshop close

16:45 – 17:15

SYMPOSIA REFRESHMENTS – *Atrium*

17:15 – 18:00	SPONSORED SYMPOSIA 1: – <i>Weston Auditorium, Atrium</i>	Sponsored by: 
18:00 – 18:15	Comfort break	
18:15 – 19:00	SPONSORED SYMPOSIA 2: – <i>Weston Auditorium, Atrium</i>	Sponsored by: 
19:15 – 22:00	WELCOME BUFFET RECEPTION – <i>Cricket Hall, Sports Village</i>	
19:20	HEART UK welcome	
19:25	Sponsor Welcome	
19:30 – 19:45	GUEST SPEAKER: UPDATE ON CVD STRATEGY – TWO YEARS ON Professor Huon Gray National Clinical Director for Heart Disease NHS England	
22:00	Evening concludes	

THURSDAY 17 SEPTEMBER		
	MEDICAL & SCIENTIFIC PROGRAMME	HEALTH CARE & PATIENTS PROGRAMME
08:00	REGISTRATION <i>Weston Auditorium Foyer, Atrium</i>	
08:30 – 09:25	REFRESHMENTS, NETWORKING AND EXHIBITION <i>Cricket Hall, Sports Village</i>	
	SESSION ONE: <i>Weston Auditorium, Atrium</i>	
09:25 – 09:30	Introduction: <i>Mr Ray Edwards, Chairman, HEART UK</i> <i>Dr Alan Rees, Medical Director, HEART UK</i> Co-chairs: Robert Cramb and Dermot Neely	
09:30 – 10.00	PLENARY SPEAKER 1: CARDIOVASCULAR RISK FACTORS – A GLOBAL PERSPECTIVE Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist International Centre for Circulatory Health St Mary's Hospital, Imperial College London, UK	
10.00 – 10:05	Discussion	

10:05 – 10:25	<p>PLENARY SPEAKER 2: CARDIO-METABOLIC RISK- SHOULD WE STILL CHOSE OUR PARENTS? Predicting risk of cardiovascular events is an imprecise art, are we edging closer to enhancing genetic and phenotypic information to improve things-discuss! Dr Henry Purcell Senior Fellow in Cardiology Royal Brompton Hospital, London, UK</p>	
10:25 – 10:30	Discussion	
10:30 – 10:50	<p>PLENARY SPEAKER 3: GUIDELINES FOR CARDIOVASCULAR DISEASE: WHERE ARE WE GOING? A comparison of the two systems used to define lipid guidelines internationally - targets-based vs, risk-based. Professor Tony Wierzbicki Consultant in Metabolic Medicine and Chemical Pathology Guy's & St Thomas Hospitals, London, UK</p>	
10:50 – 10:55	Discussion	
10:55 – 11:30	<p>REFRESHMENTS, NETWORKING AND EXHIBITION <i>Cricket Hall, Sports Village</i></p>	
	<p>SESSION TWO: <i>Weston Auditorium, Atrium</i></p>	<p>SESSION THREE: <i>N001, Atrium</i> Session sponsored by: </p>
	Co-chairs: <i>Nigel Capps and Devi Nair</i>	Co-chairs: <i>Arun Gupta and Suzanne Watkins</i>
11:30 – 12:00	<p>SPEAKER 4: THE SOUTH ASIAN PHENOTYPE: INCREASED SUSCEPTIBILITY TO TYPE 2 DIABETES AND CORONARY ARTERY DISEASE Briefing about the South Asian Phenotype and its risk factors. Dr Viswanathan Mohan Chairman & Chief of Diabetology, Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Noncommunicable Diseases Prevention & Control, IDF Centre of Education, President & Director, Madras Diabetes Research Foundation, Chennai, INDIA</p>	<p>HC SPEAKER 4: SATURATED FAT – THE DEVIL OR THE MISUNDERSTOOD NUTRIENT Recent media coverage has given saturated fat a clean bill of health, but is this view supported by the science; this presentation will review the evidence and provide recommendations for what should be told to the public. Dr Janice Harland Nutritionist HarlandHall Associates, Cirencester, UK</p>
12:00 – 12:05	Discussion	Discussion
12:05 – 12:35	<p>SPEAKER 5: PREVALENCE OF DYSLIPIDAEMIA IN INDIAN ADOLESCENTS Our study describes patterns of dyslipidemia as well as prevalence of obesity and hypertension in 2500 Indian adolescents. Dr Raman Puri Senior Interventional Cardiologist, Apollo Hospital, New Delhi Founder & Vice Chairman, Lipid Association of India, INDIA</p>	<p>HC SPEAKER 5: BLOOD PRESSURE How raised blood pressure is managed in primary care, with references to NICE guidelines and the latest research. Dr Terry McCormack GP, Whitby Group Practice, Spring Vale Medical Centre, Whitby, North Yorkshire, UK</p>
12:35 – 12:40	Discussion	Discussion

12:40 – 13:10	<p>SPEAKER 6: EMERGING ETHNIC DIFFERENCES IN CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES – EVIDENCE FROM STUDIES IN CHILDREN In the UK, people of different ethnic origins have very different risks of cardiovascular disease and type 2 diabetes. This presentation will describe research on the emerging patterns of cardiovascular risk and type 2 diabetes in children and its implications for cardiovascular prevention in the next generation. Professor Peter Whincup Population Health Research Institute, St George's, University of London, London, UK</p>	<p>HC SPEAKER 6: A PATIENTS PERSPECTIVE Ms Sonya Brennan Patient, London, UK</p>
13:10 – 13:15	Discussion	Discussion
13:15 – 14:30 (75 mins)	LUNCH, NETWORKING AND EXHIBITION <i>Cricket Hall, Sports Village</i>	
14:30 – 16:00	<p>CLINICAL LIPIDOLOGY LIVE! Interactive Session in a panel format Facilitator: <i>Alan Rees</i>, Medical Director, HEART UK</p>	
16:00 – 16:30	<p>redlaces walk HOSTS: <i>Danielle Hoad</i> – Places for People <i>Charlotte Hoare</i>, HEART UK DEPARTURE FROM: <i>Weston Auditorium, Atrium</i> FINISHES: <i>Cricket Hall, Sports Village</i></p>	
16:00 – 16:45	REFRESHMENTS, NETWORKING AND EXHIBITION <i>Cricket Hall, Sports Village</i>	
16:45 – 17:00	<p>HEART UK'S CAMPAIGNING AND SUPPORT OF HCP'S Ms Jules Payne Chief Executive, HEART UK</p>	
	<p>SESSION FOUR: <i>Weston Auditorium, Atrium</i> Chair: <i>Ray Edwards</i></p>	
17:00 – 17:05	<p>REMEMBERING DR NICK MYANT Professor Gil Thompson</p>	
17:05 – 18:05	<p>PLENARY SPEAKER 7: MYANT LECTURE: MOLECULAR GENETICS OF FAMILIAL HYPERCHOLESTEROLAEMIA : WHAT HAVE WE LEARNED AND WHERE ARE WE GOING? Professor Steve Humphries Professor of Cardiovascular Genetics, UCL, London, UK</p>	
18:05 – 19:05	<p>HEART UK AGM <i>Weston Auditorium, Atrium</i></p>	
19:30 - 20:00	<p>INDIAN INSPIRED CONFERENCE PRE DINNER DRINKS <i>Club Lounge, Club de Havilland</i></p>	
20:00 - 23:30	<p>INDIAN INSPIRED CONFERENCE DINNER AND ENTERTAINMENT <i>Comet Room, Club de Havilland</i></p>	
23:00	Bar closes	
23:30	Evening concludes	

FRIDAY 18 SEPTEMBER

MEDICAL & SCIENTIFIC PROGRAMME

HEALTH CARE & PATIENTS PROGRAMME

08:30 – 09:30

REGISTRATION, REFRESHMENTS AND EXHIBITION

Cricket Hall, Sports Village

08:35 – 09:35

MODERATED POSTER SESSION (1)

Cricket Hall, Sports Village

Judging panel:

Steve Humphries, Arun Gupta, Gil Thompson

1

RELATIONSHIP BETWEEN MEASUREMENTS OF NON-HDL-CHOLESTEROL AND LDL-CHOLESTEROL IN FAMILIAL HYPERCHOLESTEROLAEMIA

J Abreu¹, K Haralambos¹, P Ashfield-Watt¹, R Edwards², R Gingell², D Townsend², D Datta², IFW McDowell^{1,2}

¹Cardiff University, Wales Heart Research Institute, Cardiff, Wales, UK

²All Wales FH Cascade Testing Service, UK

2

WHERE HAVE ALL THOSE FAMILIAL HYPERCHOLESTEROLAEMIA PATIENTS GONE?

J Breen, E Neves, L Priestley-Barnham, M Barbir

Royal Brompton and Harefield NHS Trust Harefield Hospital Hill End Road Harefield UB9 6JH

3

PEDIATRIC CHOLESTEROL SCREENING IN ITALY: THE SPIF PROJECT

PS Buonomo^{1}, BM Polizzi², M Macchiaiolo¹, G Mastrogorgio¹, M Scalzone¹, P Casucci³, A Correr⁴, L Lughetti⁵, A Bartuli¹*

¹Rare Diseases and Medical Genetics, Bambino Ges Children's Hospital Rome, ITALY

²Ministry of Health, Rome, ITALY

³Health Care Services, Perugia, ITALY

⁴Pediatric Metabolic and Rare Diseases, SS. Annunziata / Santobono Pausilipo Hospital, Naples, ITALY

⁵Pediatrics, Policlinic of Modena, Modena and Reggio Emilia University, Modena, ITALY

4

THE NORTHERN IRELAND FAMILIAL HYPERCHOLESTEROLAEMIA CASCADE SCREENING SERVICE

**MH Cather¹, IS Young², DP Nicholls², KE Ryan², CM Loughrey², M O'Kane³, EM Proctor³, PC Sharpe⁴, JP McCullough⁴, E Hanna⁵, J Chestnutt⁵, J Donnelly⁵, T Trinick⁶, KA Lyttle⁶, PJ Hart¹, CA Graham¹*

¹. Regional Genetics Laboratories, BCH. ². Belfast HSCT: RVH, BCH. ³. Western HSCT, AH. ⁴. Southern HSCT, CAH. ⁵. Northern HSCT, AAH. ⁶. South Eastern HSCT, UHD

5

FROM NICE GUIDANCE TO CLINICAL PRACTICE: THE CHALLENGE OF SETTING UP A SERVICE FOR FAMILIAL HYPERCHOLESTEROLAEMIA.

A Cazeaux, S Balasingham, M Watson

Wessex Clinical Genetics, UK

6

THE RELATIONSHIP BETWEEN CIRCULATING MICRORNA AND LIPID INDICES.

J Eastwood², MJ Caslake², D Preiss², C Packard², I Godber¹, L Denby², R Sodi^{1,2}

¹Department of Biochemistry, NHS Lanarkshire, Wishaw, UK

²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK

7

AUDIT OF THE INVESTIGATION OF PATIENTS WITH A TOTAL CHOLESTEROL OF >7.5MMOL/L AFTER A WRITTEN ALERT TO PRIMARY CARE PRACTITIONERS

E Fayle¹, H Ashby¹, S Cartwright², M Labib¹

¹Department of Clinical Biochemistry, Dudley Group Hospitals NHS Foundation Trust, Dudley, UK

²Keeling House Surgery, CCG Lead - Integration and Partnerships, Dudley CCG , UK

8

FAMILIAL HYPERCHOLESTEROLAEMIA: AN AUDIT OF INTEGRATED PAEDIATRIC CLINIC CARE

E Garrett, C Heming, A Blackstock, D Nair, S Humphries, R Chodhari

Royal Free Hospital Pond Street London, UK

9

OPTIMISING DETECTION AND MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH) – REVISION OF THE FH AUDIT TOOL TO MONITOR LIPID LEVELS

P Green¹, J Payne², SE Humphries³, D Neely⁴, R Gingell⁵, C Lunken⁶, G Oliver⁷, S Boley², R Helm³

¹Chief Clinical Officer, NHS Medway Clinical Commissioning Group

²HEART UK

³Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Sciences, University College London

⁴Department of Clinical Biochemistry, Royal Victoria Infirmary

⁵FH Clinical Nurse Specialist, Betsi Cadwaladr University Health Board

⁶Clinical Lead for Familial Hypercholesterolaemia, University College London Hospital

⁷Quality Improvement Manager, Yorkshire and Humber Strategic Clinical Network

⁸Director of Evidence and Analytics BMJ

10

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA – SUMMARY OF CASES DETECTED AT THE BRISTOL GENETICS LABORATORY

A Hills¹, J Honeychurch¹, P Dean¹, G Dennis¹, M Greenslade¹, M Barbir², J Breen², C Dawson³, N El-Farhan⁴, R Ayling⁵, A Sharma⁶, G Bayly⁷, M Williams¹

¹Bristol Genetics Laboratory, UK; ²Harefield Hospital, UK; ³Queen Elizabeth Hospital, Birmingham, UK; ⁴Royal Gwent Hospital, UK; ⁵Derriford Hospital, UK

⁶Torbay Hospital, UK; ⁷University Hospital Bristol, UK

11

MODERNISING WORKFLOWS FOR HIGH THROUGHPUT TESTING FOR FAMILIAL HYPERCHOLESTEROLAEMIA: HOW TO DELIVER A COST EFFECTIVE GENETIC TESTING SERVICE

J Honeychurch¹, A Hills¹, P Dean¹, M Greenslade¹, C Buxton¹, G Woodward¹, G Dennis¹, G Bayley², L Gritzmacher², K Haralambos³, M Williams¹

¹Bristol Genetics Laboratory, Bristol, UK

²Bristol Royal Infirmary, Bristol, UK

³University Hospital of Wales, Cardiff, UK

12

SPECIALIST FAMILIAL HYPERCHOLESTEROLAEMIA (FH) NURSES IN PRIMARY CARE FOR IDENTIFICATION OF FH INDEX CASES

Z Jayne, J Lungley, D Harvey, A Stuart¹, DR Nair

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, UK

¹Park End Surgery, 3 Park End, London, UK

13

THE ROLE OF THE FAMILIAL HYPERCHOLESTEROLAEMIA CLINICAL NURSE SPECIALIST IN MANAGING AND EMPOWERING ADOLESCENTS AND YOUNG PEOPLE WITH FH TO TAKE

CONTROL OF THEIR HEALTH

L Priestley-Barnham, J Breen, E Neves, M Barbir*

Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Hill End Road, Harefield, Uxbridge, Middlesex, UK

14

LIPOPROTEIN PHOSPHOLIPASE A2, HIGH SENSITIVITY C REACTIVE PROTEIN AND CAROTID INTIMA MEDIA THICKNESS IN CARDIOVASCULAR RISK ASSESSMENT FOR A SOUTH ASIAN POPULATION

N Rao, A Jain, D Harvey, JW Persaud¹, DR Nair

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, UK

¹Health Service Laboratories, Royal Free London NHS Foundation Trust, London, UK

15

DEVELOPMENT OF A REGIONAL FAMILIAL HYPERCHOLESTEROLAEMIA (FH) GENETIC CASCADE TESTING SERVICE FOR THE NORTH OF ENGLAND

R Tomlin¹, PE Carey², J Frater², P McKenna², JU Weaver², A Luvali², G Pilkington⁴, M Wright³, J Allen³, M Power³, RDG Neely^{2}*

¹Northern England Strategic Clinical Network (NESCN), ²North of England Lipid Advisory Group, ³NIHR Diagnostic Evidence Co-operative Newcastle, ⁴Northern CCG Forum

16

ASSESSMENT AND INTERPRETATION OF VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS) IN FAMILIAL HYPERCHOLESTEROLAEMIA.

E Watson¹, A Hills¹, J Honeychurch¹, M Williams¹

¹Bristol Genetics Laboratory, Bristol, UK

UNMODERATED POSTER SESSION (2)

Cricket Hall, Sports Village

17

LOWER: A REGISTRY EVALUATING LONG-TERM LOMITAPIDE USE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

D Blom¹, JJP Kastelein², D Larrey³, L Makris⁴, C Schwamlein⁵, H Phillips⁶, J Underberg⁷

¹Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa; ²Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands; ³Montpellier School of Medicine, IRB-INSERM1040, Montpellier, France; ⁴Stathmi, Inc., New Hope, PA, USA; ⁵Pharmacovigilance, Inc., San Francisco, CA USA; ⁶Aegerion Pharmaceuticals Ltd., UK; ⁷Department of Medicine, New York University Langone Medical Center, New York, NY, USA

18

PAEDIATRIC FH CLINIC BORN OUT OF A CASCADE TESTING SERVICE

R Chodhari, A Gullivan**, D Harvey**, E Garrett*, A Jain**, D R Nair***

*Department of Paediatrics, Royal Free London Foundation NHS Trust, London, UK

**Department of Clinical Biochemistry, Royal Free London Foundation NHS Trust, London, UK

19

FAMILIAL HYPERCHOLESTEROLAEMIA SERVICE EVALUATION

J Donnelly(1), E Hanna, J Chestnutt(1), S Gidwani(1), JM cAloon(2)*

Lipid Clinic (1) & Paediatric Clinic(2), Antrim Area Hospital, Northern Health and Social Care trust. Antrim Hospital Laboratory Bush Road Antrim, N IRELAND

20

THE USE OF LOW DOSE CONTINUOUS INSULIN INFUSION FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA INDUCED PANCREATITIS IN NON-DIABETIC PATIENTS

T Doris¹, B Messer¹, RDG Neely²

1. Department of Intensive Care Medicine, Royal Victoria Infirmary, Newcastle upon Tyne
2. Department of Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne

21

DEVELOPMENT OF INTEGRATED INFORMATION TECHNOLOGY (IT) SYSTEM FOR FAMILIAL HYPERCHOLESTEROLAEMIA SERVICES IN ENGLAND

¹K Haralambos, ²L Gritzmacher, ³IFW McDowell, ²G Bayly, ⁴A Taylor, ⁵J Whitmore, ⁶M Williams, ⁶A Hills, ⁷J Payne*

¹Cardiff University, Cardiff, UK; ²University Hospitals Bristol NHS Foundation Trust, Bristol, UK; ³Cardiff and Vale NHS University Health Boards, Cardiff, UK; ⁴Royal United Hospital Bath NHS Foundation trust, Bath UK; ⁵British Heart Foundation, UK; ⁶Bristol Genetics Laboratory, Bristol, UK; ⁷Heart UK.

22

HIGH HDL CHOLESTEROL- IS IT REALLY PROTECTIVE?

A Jain, J Defesche, D RNair*

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, UK

*Molecular Diagnostic Laboratory, Department of Vascular Medicine, Academic Medical centre, Amsterdam, NL-1105 AZ, THE NETHERLANDS

23

IS THE LIVER SUFFERING IN GUJARATI INDIANS IN NORTH LONDON?: A POPULATION BASED STUDY

K Neukam^{1,2}, S Bhagani¹, A Rodger³, J Oben^{4,5}, A Jain⁶, D Nair⁶

¹Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, NW3 2QG, UK. ² Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, 41014 Seville, Spain. ³Department of Infection and Population Health, University College London, NW3 2PF, UK. ⁴Institute for Liver and Digestive Health, University College London, NW3 2PF, UK. ⁵Guy's and St Thomas' Hospital NHS Foundation Trust, London, SE1 9RT, UK. ⁶Department of Clinical Biochemistry, Royal Free London Foundation NHS Trust, London, NW3 2QG, UK.

24

HIDDEN ABNORMALITIES IN LIPOPROTEINS AND HDL FUNCTIONALITY IN OBESE PATIENTS COMPARED TO AGE AND SEX-MATCHED CONTROLS

Y Liu¹, S Hama¹, JD Schofield^{1,2}, R Yadav¹, M France², BJ Ammori¹, T Siahmansur¹, S Kwok², A Syed¹, PN Durrington¹, H Soran^{1,2}

¹Lipoprotein Research Group, Core Technology Facility, University of Manchester, UK

²Cardiovascular Trials Unit, University Department of Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

25

SEVERE HYPERCHOLESTEROLEMIA AND XANTHOMAS: NOT ONLY FAMILIAL HYPERCHOLESTEROLEMIA

G Mastrogiorgio¹, PS Buonomo¹, S Calandra², C Rabacchi³, S. Bertolini⁴, C Cortese⁵, M Macchiaiolo¹, I Rana¹, M Scalzone¹, A Bartuli¹

¹Rare Diseases and Medical Genetics, Bambino Gesù Children's Hospital Rome, ITALY;

²Department of Biomedical Sciences, metabolic and neurological diseases, University of Modena and Reggio Emilia, Modena, ITALY

³Department of Life Sciences, University of Modena and Reggio Emilia, ITALY

⁴Department of Internal Medicine, University of Genova; ITALY

⁵Department of Laboratory Medicine, Policlinico Tor Vergata, Rome, ITALY

26

ONE BORN EVERY MINUTE

L Priestley-Barnham, J Breen, E Neves, A Bryant, M Barbir

Royal Brompton and Harefield NHS Trust, Harefield Hospital, Hill End Road, Harefield, Middlesex, UK

27

PATIENT EXPERIENCE OF A LIPOPROTEIN APHERESIS SERVICE IN THE UK

A Pottle, E Neves, V Kale, C Huggett, E Lee, V Ellis, C Browne, P Sodi*

Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, London. UK

	<p>28 CUTANEOUS MICROVASCULAR ENDOTHELIAL FUNCTION DIFFERS IN YOUTH ACCORDING TO CHRONIC EXERCISE TRAINING STATUS <i>*DM Roche^a, K Holloway^a, M Garrard^b, V Unnithan</i> ^a Dept. of Health Sciences, Liverpool Hope University, Liverpool, UK ^b Leeds Beckett University, Leeds, UK ^c Staffordshire University, Stoke-on-Trent, UK</p> <p>29 A COMPARISON OF LOW AND HIGH DOSE ATORVASTATIN ON LIPOPROTEINS QUALITY, HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY AND INFLAMMATORY CYTOKINES OVER ONE YEAR IN TYPE 2 DIABETES: THE PROTECTION AGAINST NEPHROPATHY IN DIABETES WITH ATORVASTATIN (PANDA) TRIAL <i>T Siahmansur¹, Y Liu¹, S Kwok^{1,2}, JD Schofield^{1,2}, M Gittins¹, M France¹, N Younis¹, M Gibson¹, PN Durrington, MK Rutter¹, H Soran^{1,2}</i> ¹ University of Manchester, 46 Grafton Street, Manchester, UK ² Cardiovascular Trials Unit, The Old St Mary's Hospital, Hathersage Road, Manchester, UK</p>
	<p>SESSION FIVE: <i>Weston Auditorium, Atrium</i></p>
09.45 – 09:50	<p>Opening remarks: <i>Dr Alan Rees, Medical Director, HEART UK</i></p>
	<p>Co-chairs: <i>Linda Main and Devi Nair</i></p>
09:50 – 10:40	<p>PLENARY SPEAKER 8: OBESITY AND CARDIOVASCULAR DISEASE; BEYOND BODY WEIGHT LOSS Although weight loss is commonly advocated to reduce risk of cardiovascular disease in overweight and obese individuals, evidence will be presented to support the notion that improving nutritional quality, reducing sedentary time and increasing physical activity are key lifestyle risk factors which should be assessed and targeted. Reducing waist circumference and improving cardiorespiratory fitness will be proposed as targets that may be as important, if not more, than weight loss. Professor Jean-Pierre Després Director of research in Cardiologie, Québec Heart and Lung Institute, Québec, CANADA</p>
10:40 – 10:50	Discussion
10:50 - 11:20	<p>REFRESHMENTS AND EXHIBITION <i>Cricket Hall, Sports Village</i></p>
	<p>SESSION SIX: <i>Weston Auditorium, Atrium</i></p>
	<p>Co-chairs: <i>Michael France and Carol Shoulders</i></p>
11:20 – 11:35	<p>SPEAKER 9: IDENTIFYING PATIENTS WITH FH IN PRIMARY CARE What happened next use of the Medway FH audit tool in England & Wales. Dr Peter Green Chief Clinical Officer, NHS Medway Clinical Commissioning Group, Kent, UK</p>
11:35 – 11:40	Discussion
11:40 – 11:55	<p>SPEAKER 10: FH IN WALES Mr Robert Gingell FH Nurse, Wales, UK</p>
11:55 – 12:00	Discussion
	<p>SESSION SEVEN: <i>N001, Atrium</i></p>
	<p>Co-chairs: <i>Baldeesh Rai and Alison Pottle</i></p>
11:20 – 11:45	<p>HC SPEAKER 7: DOES DIETARY CARBOHYDRATE AFFECT HEART HEALTH? This presentation will examine why different types of dietary carbohydrate, chiefly sugars and fibre have been implicated in promoting and protecting us against coronary heart disease. Professor Bruce Griffin Professor of Nutritional Metabolism, University of Surrey, Guildford, Surrey, UK</p>
11:45 – 11:50	Discussion
11:50 – 12:15	Discussion

12:00 – 12:15	<p>SPEAKER 11: BHF FUNDED FH PROJECT – AN UPDATE An update on the BHF funded FH project – the journey so far, current state of play and plans for the future <i>Ms Joanne Whitmore</i> FH Clinical Lead, British Heart Foundation, London, UK</p>	<p>HC SPEAKER 8: ALCOHOL – PROS AND CONS FOR CARDIOVASCULAR HEALTH <i>Dr Michael Holmes</i> Oxford, UK</p>
12:15 – 12:20	Discussion	12:15 – 12:20 Discussion
12:20 – 13:20	<p>LUNCH, NETWORKING AND EXHIBITION <i>Cricket Hall, Sports Village</i></p>	
	<p>ABSTRACTS OF FREE COMMUNICATIONS – MEDICAL & SCIENTIFIC <i>Weston Auditorium, Atrium</i></p> <p>Co-Chairs: <i>Gordon Ferns and Julian Halcox</i></p>	<p>ABSTRACTS OF FREE COMMUNICATIONS – HEALTHCARE & PATIENTS <i>N001, Atrium</i></p> <p>Co-Chairs: <i>Linda Edmunds and Tricia Kennerley</i></p>
13:20 – 13:30	<p>(1) MOLECULAR SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA IN THE NORTH EAST OF ENGLAND USING A TWO TIER APPROACH <i>R Chaston¹, S Boras¹, A Curtis^{1*}, E Stevenson¹, RDG Neely², D Bourn², C McAnulty²</i> ¹NewGene, UK ²Newcastle Upon Tyne NHS Foundation Trust, UK</p>	<p>(5) WEB BASED TOOLS TO ASSESS ELIGIBILITY FOR GENETIC TESTING FOR FAMILIAL HYPERCHOLESTEROLAEMIA (FH) <i>PAL Ashfield-Watt^{1*}, K Haralambos¹, B Sharif¹, R Edwards², R Gingell², D Townsend², D Datta², IFW McDowell^{1, 2}</i> ¹Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, Wales, UK ²Wales FH Cascade Testing Service, UK</p>
13:30 – 13:35	Discussion	Discussion
13:35 – 13:45	<p>(2) AN APPROACH TO GENETIC DIAGNOSIS OF SEVERE HYPERTRIGLYCERIDAEMIA <i>N Hoshi¹, A Jain¹, JW Persaud², J Defesche³, DR Nair¹</i> 1 Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, UK 2 Health Service Laboratories, Royal Free London NHS Foundation Trust, London, UK 3 Diagnostic Laboratory, Department of Vascular Medicine, Academic Medical Centre, Amsterdam, THE NETHERLANDS</p>	<p>(6) DEVELOPMENT OF AN E-LEARNING PROGRAM ON FAMILIAL HYPERCHOLESTEROLAEMIA (FH) FOR PRIMARY CARE <i>R Edwards^{1*}, R Gingell¹, D Townsend¹, N Lewis², D Datta², IFW McDowell²</i> ¹All Wales FH Cascade Testing Service Cardiff UK ²University Hospital of Wales, Cardiff and Vale Health Board, Cardiff, UK</p>
13:45 – 13:50	Discussion	Discussion
13:50 – 14:00	<p>(3) EFFECT OF BARIATRIC SURGERY ON HDL QUANTITY AND QUALITY <i>Y Liu¹, T Siahmansur¹, S Hama¹, JD Schofield^{1,2}, R Yadav², M France², S Kwok², R Donn¹, A Stevens¹, BJ Ammori¹, A Syed¹, PN Durrington¹, H Soran^{1,2}</i> ¹Lipoprotein Research Group, Core Technology Facility, University of Manchester, Manchester, UK ²Cardiovascular Trials Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK</p>	<p>(7) FAMILY BASED GENETIC ASSOCIATION ANALYSIS FOR GENETIC VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS) IN FAMILIAL HYPERCHOLESTEROLAEMIA <i>K Haralambos^{1*}, SD Whatley², R Edwards³, R Gingell³, D Townsend³, P Holmans¹, A Clarke¹, DBN Datta², R Butler², S Palmer-Smith², M Wood², IFW McDowell²</i> ¹Cardiff University, Cardiff, UK ²University Hospital of Wales, Cardiff and Vale Health Board, Cardiff, UK ³All Wales FH Cascade Testing Service, All Wales Medical Genetics Service, Cardiff, UK</p>
14:00 – 14:05	Discussion	Discussion
14:05 – 14:15	<p>(4) IDENTIFICATION OF TWO RARE APOE MUTATIONS ASSOCIATED WITH FAMILIAL HYPERCHOLESTEROLAEMIA IN THE NORTH OF ENGLAND <i>C McAnulty², S Boras⁴, A Curtis⁴, R Chaston⁴, E Stevenson⁴, D Bourn², S</i></p>	<p>(8) ATHEROSCLEROSIS IN MONOGENIC FAMILIAL HYPERCHOLESTEROLAEMIA VERSUS POLYGENIC HYPERCHOLESTEROLAEMIA <i>M Sharifi^{1 2}, A Gallivan^{1 2}, D Harvey¹, K Wah Li², M Futema², J Cooper², S Humphries²,</i></p>

	<p><i>Fairgrieve², M Anderson³, M Burns⁴, RDG Neely^{1*}</i> ¹The Lipid Clinic, ²Northern Genetics Service and ³Great North Children's Hospital, Newcastle Upon Tyne NHS Foundation Trust, ⁴NewGene, ⁵James Cook Hospital, Middlesbrough, UK</p>	<p><i>D Nair¹</i> ¹ Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, Pond Street, London UK ² Centre for Cardiovascular Genetic, University College London, The Rayne Institute, University Street, London, UK</p>
14:15 – 14:20	Discussion	Discussion
14:20 – 14:30	Comfort break (and to work out prize winners)	
14:30 – 15:30	<p>CLOSING INTERACTIVE DEBATE: A COURTROOM DRAMA <i>Weston Auditorium, Atrium</i></p> <p>STATINS FOR THE MASSES - MEDICALISATION OF HEALTHY PEOPLE</p> <p>THE CHARGE: That it is neither practical or appropriate to give statins to the masses.</p> <p>With the reduction in the threshold for considering medication for primary prevention to 10% 10 yr CVD risk many more millions of people in the UK are eligible for statin treatment. The potential for side effects appears real and the absolute benefit may not be significant. The house believes therefore that we may be at risk of medicalising healthy people and that statins are not always the answer.</p> <p>JUDGE: <i>Professor Elizabeth Hughes</i>, Director and Dean of Education and Quality, Health Education England (London and South East) PROSECUTION: <i>Dr Bill Simpson</i>, Consultant Chemical Pathologist, Clinical Biochemistry Laboratory, NHS Grampian DEFENCE: <i>Professor Darrel Francis</i>, Professor of Cardiology, Faculty of Medicine, National Heart & Lung Institute, Imperial College London</p>	
15:30 – 15:40	<p>Presentation of abstract prizes <i>Dr Alan Rees, Medical Director, HEART UK</i></p>	
15:40 – 15:45	<p>Introduction to the HEART UK 30th Annual Conference CHOLESTEROL – THE EVOLVING STORY. A CELEBRATION OF 30 YEARS OF LIPIDOLOGY <i>Edinburgh Conference Centre, Heriot Watt University, Edinburgh, Scotland, UK</i> Wednesday 6 – Friday 8 July 2016 Myant lecturer: <i>Professor Chris Packard</i>, Glasgow, Scotland, UK LOCAL HOST: <i>Dr Peter Rae</i>, NHS Lothian</p>	
15:45	Conference concludes	